CVS Surges Past Q2 Expectations, Raises 2026 Outlook as Aetna Recovers

CVS Health turned heads in its latest quarterly report, trumping Wall Street earnings and revenue forecasts with ease. The company's second-quarter numbers show that its once-struggling insurance arm, Aetna, is finally gaining traction, contributing to a more optimistic financial outlook for 2026.

The healthcare giant now anticipates adjusted earnings per share between $7.90 and $8.10 for the full year, a solid improvement over its previous $7.30 to $7.50 range. Revenue expectations also jumped, with CVS targeting at least $414 billion, up from the prior floor of $405 billion.

Despite these upbeat figures, the market reacted somewhat tepidly- shares dipped over 8% in premarket trading. Sometimes stellar quarterly results don't always translate into immediate investor enthusiasm, especially when a company tempers expectations with caution surrounding ongoing medical cost pressures and economic uncertainties.

Digging into the details, CVS reported better-than-expected sales across all its units: insurance, retail pharmacy, and health services. The insurance side, particularly Aetna, has been under pressure due to elevated medical costs tied to Medicare Advantage plans. Yet recent efforts like membership adjustments, plan modifications, and market exits seem to be paying dividends.

>

Aetna shaved its medical benefit ratio to 87.4%, down from 89.9% a year ago and better than the 89.8% analysts anticipated. This lower ratio signals the unit is paying less in claims relative to premiums it collects, driving improved profitability.

The insurance business posted $37.54 billion in revenue, beating analyst estimates by a comfortable margin. CVS attributed some of the year-over-year gains to strong government plan performance and the absence of a premium deficiency reserve that weighed on the prior period.

CVS' pharmacy and consumer wellness arm slightly outpaced projections with $33.82 billion in sales, fueled by activity across its 9,000-plus retail pharmacies offering everything from prescriptions to vaccinations and diagnostics.

Meanwhile, Health Services, which includes pharmacy benefit manager Caremark, saw an 11.5% revenue increase year-over-year, bringing in $51.8 billion and surpassing analyst forecasts. Caremark's role in negotiating drug prices and managing formularies clearly continues to add value.

On a new venture note, CVS teamed up with Eli Lilly to roll out easier access for weight management treatments like the obesity injection Zepbound and the newly approved pill Foundayo through the CVS Health app starting in Q4. This move aims to tap into growing consumer demand for direct-to-patient healthcare solutions.

While CVS' turnaround shows promise, balancing the cost challenges in healthcare will be a test moving forward. Still, with all parts of the business contributing positively, it's a reminder that even longstanding giants can find ways to adapt in a shifting industry.